耐赋康®7项最新真实世界数据将亮相第18届IgA肾病国际研讨会

Core Insights - Nefecon® (耐赋康®) will present seven new real-world data studies at the 18th International IgA Nephropathy Symposium (IIgANN 2025), showcasing its efficacy and safety in treating IgA nephropathy [1][2] - The data highlights significant clinical value in "etiological treatment, early intervention, and long-term treatment," reinforcing Nefecon®'s position as a cornerstone therapy for IgA nephropathy [2][3] Group 1: Clinical Efficacy and Safety - Real-world evidence from top hospitals in China demonstrates that Nefecon® significantly reduces proteinuria and stabilizes renal function, particularly with over nine months of extended treatment [2][4] - Nefecon® is the only drug recommended in both international and domestic guidelines for the etiological treatment of IgA nephropathy, establishing its leading role in clinical practice [3][11] Group 2: Regulatory Approvals and Market Position - Nefecon® was successfully included in the National Medical Insurance Drug List in November 2024 and received approval for production expansion from the National Medical Products Administration in August 2025 [3] - It is the first IgA nephropathy treatment drug fully approved by regulatory agencies in multiple regions, including China, the USA, and Europe, enhancing its market presence [3][11] Group 3: Research Studies Presented - A 12-month study indicates that Nefecon® treatment significantly lowers proteinuria and protects renal function compared to traditional therapies [4] - A retrospective cohort study over six months shows that Nefecon® effectively reduces proteinuria and improves renal function in Chinese patients, supporting its potential as a first-line treatment [6] - Case reports demonstrate the efficacy of Nefecon® in patients with concurrent hepatitis B virus infection, providing evidence for its safe use in this population [7]